January’s Journal Club

Topic: Promising new regimens or studies of uncertain value?

Diacon et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380: 986-93.

Presenter: Jurgens Peters, London School of Hygiene and Tropical Medicine

Chair: Patrick Phillips, MRC Clinical Trials Unit

Time: 1:00-1.50 pm, 31 January 2013

Venue: Room 402,  MRC Clinical Trials Unit, Aviation House, 125 Kingsway

Directions: See http://www.ctu.mrc.ac.uk/about_us/contact_details.aspx. The entrance is opposite Holborn tube station and looks like the entrance to a church building.

* External attendees will need to wait at reception and be taken to the meeting room. If you plan to attend, please contact Patrick Phillips on ppp@ctu.mrc.ac.uk so that reception know who is expected. *

We urgently need better drugs for TB. This would allow for shorter first line therapy and treatment for drug resistant TB this is safer and more effective with patients experiencing fewer unpleasant side effects.

This paper describes interesting data on novel drugs and combinations that seem to exhibit good ‘early bactericidal activity’. These include a regimen that might work for MDR-TB.

With the FDA advisory committee recently recommending limited approval of Bedaquiline for MDR-TB on the basis of culture conversion data from Phase II studies, the use of surrogate outcomes is topical.

Join us to discuss the design and evaluation of new TB regimens, the value of surrogate outcomes, and the future of TB therapy.

The paper is available here.


Leave a comment

Filed under Uncategorized

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s